Jesper Enander

Jesper Enander

Auto-generated profile, based on publicly available information

Jesper Enander

Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet, and Stockholm Health Care Services, Region Stockholm, Sweden

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2014 in Molecular Psychiatry
Verified
Journal Article
Open access
VVValerie Voon
Valerie Voon
KDK Derbyshire
K Derbyshire
CRC Rück
C Rück
MIM A Irvine
M A Irvine
YWY Worbe
Y Worbe
EBE T Bullmore
E T Bullmore
Why do we repeat choices that we know are bad for us? Decision making is characterized by the parallel engagement of two distinct systems, goal-directed and habitual, thought to arise from two computational learning mechanisms, model-based and model-free. The habitual system is a candidate source of pathological fixedness. Using a decision task that measures the contribution to learning of either mechanism, we show a bias towards model-free (habit) acquisition in disorders involving both natural (binge eating) and artificial (methamphetamine) rewards, and obsessive-compulsive disorder. This favoring of model-free learning may underlie the repetitive behaviors that ultimately dominate in these disorders. Further, we show that the habit formation bias is associated with lower gray matter volumes in caudate and medial orbitofrontal cortex. Our findings suggest that the dysfunction in a common neurocomputational mechanism may underlie diverse disorders involving compulsion.

21 February 2012 in Psychological Medicine
Verified
Journal Article
Open access
PDF file
EAE. Andersson
E. Andersson
JEJ. Enander
J. Enander
PAP. Andrén
P. Andrén
EHE. Hedman
E. Hedman
BLB. Ljótsson
B. Ljótsson
CRC. Rück
C. Rück
Background: Cognitive behaviour therapy (CBT) is an effective treatment for obsessive–compulsive disorder (OCD) but access to CBT is limited. Internet-based CBT (ICBT) with therapist support is potentially a more accessible treatment. There are no randomized controlled trials testing ICBT for OCD. The aim of this study was to investigate the efficacy of ICBT for OCD in a randomized controlled trial.Method: Participants (n=101) diagnosed with OCD were randomized to either 10 weeks of ICBT or to an attention control condition, consisting of online supportive therapy. The primary outcome measure was the Yale–Brown Obsessive Compulsive Scale (YBOCS) administered by blinded assessors.Results: Both treatments lead to significant improvements in OCD symptoms, but ICBT resulted in larger improvements than the control condition on the YBOCS, with a significant between-group effect size (Cohen'sd) of 1.12 (95% CI 0.69–1.53) at post-treatment. The proportion of participants showing clinically significant improvement was 60% (95% CI 46–72) in the ICBT group compared to 6% (95% CI 1–17) in the control condition. The results were sustained at follow-up.Conclusions: ICBT is an efficacious treatment for OCD that could substantially increase access to CBT for OCD patients. Replication studies are warranted.

1 August 2016 in Clinical Psychology Review
Verified
Journal Article
Open access
AHAmy Harrison
Amy Harrison
LCLorena Fernández de la Cruz
Lorena Fernández de la Cruz
JEJesper Enander
Jesper Enander
Joaquim RaduàJoaquim Raduà
Joaquim Raduà
DMDavid Mataix-Cols
David Mataix-Cols
Body dysmorphic disorder (BDD) is a chronic and disabling psychiatric disorder unlikely to remit without treatment. A systematic review and meta-analysis of randomized controlled trials (RCTs) of cognitive-behavioral therapy (CBT) for BDD was conducted, including published and unpublished trials to 26th November 2015. Primary outcomes were validated BDD measures; secondary outcomes included depression and insight. Meta-regressions were conducted to examine potential effects of variables on the primary outcome, including socio-demographic variables, comorbidity, symptom severity/duration, concomitant medication, treatment duration, and methodological quality of the RCTs. Seven RCTs (N=299) met inclusion criteria. CBT was superior to waitlist or credible psychological placebo in reducing BDD (7 studies; delta=-1.22, 95% CI=-1.66 to -0.79) and depression symptoms (5 studies; delta=-0.49, 95% CI=-0.76 to -0.22). CBT was associated with improvements in insight/delusionality (4 studies; delta=-0.56, 95% CI=-0.93 to -0.19). Improvement in BDD was maintained after 2-4months follow-up (3 studies; delta=-0.89, 95% CI=-1.24 to -0.54). Meta-regression analyses did not reveal any significant predictors of outcome. CBT is an efficacious treatment for BDD but there is substantial room for improvement. The specificity and long-term effects of CBT for BDD require further evaluation using credible control conditions. Additional trials comparing CBT with pharmacological therapies, as well as their combination, are warranted. Tele-care options, such as Internet-based CBT, hold great promise to increase access to evidence-based treatment for a majority of patients who need it and should be evaluated further.

3 November 2015 in Translational Psychiatry
Verified
Journal Article
Open access
PDF file
VVValerie Voon
Valerie Voon
KBK Baek
K Baek
JEJ Enander
J Enander
YWY Worbe
Y Worbe
Laurel S. MorrisLaurel S. Morris
Laurel S. Morris
NDN Daw
N Daw
Our decisions are based on parallel and competing systems of goal-directed and habitual learning, systems which can be impaired in pathological behaviours. Here we focus on the influence of motivation and compare reward and loss outcomes in subjects with obsessive-compulsive disorder (OCD) on model-based goal-directed and model-free habitual behaviours using the two-step task. We further investigate the relationship with acquisition learning using a one-step probabilistic learning task. Forty-eight OCD subjects and 96 healthy volunteers were tested on a reward and 30 OCD subjects and 53 healthy volunteers on the loss version of the two-step task. Thirty-six OCD subjects and 72 healthy volunteers were also tested on a one-step reversal task. OCD subjects compared with healthy volunteers were less goal oriented (model-based) and more habitual (model-free) to reward outcomes with a shift towards greater model-based and lower habitual choices to loss outcomes. OCD subjects also had enhanced acquisition learning to loss outcomes on the one-step task, which correlated with goal-directed learning in the two-step task. OCD subjects had greater stay behaviours or perseveration in the one-step task irrespective of outcome. Compulsion severity was correlated with habitual learning in the reward condition. Obsession severity was correlated with greater switching after loss outcomes. In healthy volunteers, we further show that greater reward magnitudes are associated with a shift towards greater goal-directed learning further emphasizing the role of outcome salience. Our results highlight an important influence of motivation on learning processes in OCD and suggest that distinct clinical strategies based on valence may be warranted.

2 February 2016 in BMJ
Verified
Journal Article
Open access
PDF file
JEJesper Enander
Jesper Enander
EAErik Andersson
Erik Andersson
DMDavid Mataix-Cols
David Mataix-Cols
LLLinn Lichtenstein
Linn Lichtenstein
KAKatarina Alström
Katarina Alström
CRChristian Rück
Christian Rück
Objectives To evaluate the efficacy of therapist guided internet based cognitive behavioural therapy (CBT) programme for body dysmorphic disorder (BDD-NET) compared with online supportive therapy. Design A 12 week single blind parallel group randomised controlled trial. Setting Academic medical centre. Participants 94 self referred adult outpatients with a diagnosis of body dysmorphic disorder and a modified Yale-Brown obsessive compulsive scale (BDD-YBOCS) score of ≥20. Concurrent psychotropic drug treatment was permitted if the dose had been stable for at least two months before enrolment and remained unchanged during the trial. Interventions Participants received either BDD-NET (n=47) or supportive therapy (n=47) delivered via the internet for 12 weeks. Main outcome measures The primary outcome was the BDD-YBOCS score after treatment and follow-up (three and six months from baseline) as evaluated by a masked assessor. Responder status was defined as a ≥30% reduction in symptoms on the scale. Secondary outcomes were measures of depression (MADRS-S), global functioning (GAF), clinical global improvement (CGI-I), and quality of life (EQ5D). The six month follow-up time and all outcomes other than BDD-YBOCS and MADRS-S at 3 months were not pre-specified in the registration at clinicaltrials.gov because of an administrative error but were included in the original trial protocol approved by the regional ethics committee before the start of the trial. Results BDD-NET was superior to supportive therapy and was associated with significant improvements in severity of symptoms of body dysmorphic disorder (BDD-YBOCS group difference −7.1 points, 95% confidence interval −9.8 to −4.4), depression (MADRS-S group difference −4.5 points, −7.5 to −1.4), and other secondary measures. At follow-up, 56% of those receiving BDD-NET were classed as responders, compared with 13% receiving supportive therapy. The number needed to treat was 2.34 (1.71 to 4.35). Self reported satisfaction was high. Conclusions CBT can be delivered safely via the internet to patients with body dysmorphic disorder. BDD-NET has the potential to increase access to evidence based psychiatric care for this mental disorder, in line with NICE priority recommendations. It could be particularly useful in a stepped care approach, in which general practitioner or other mental health professionals can offer treatment to people with mild to moderate symptoms at low risk of suicide. Trial registration ClinicalTrials.gov ID: NCT02010619.

1 July 2015 in JAMA Psychiatry
Verified
Journal Article
Open access
PDF file
EAErik Andersson
Erik Andersson
EHErik Hedman
Erik Hedman
JEJesper Enander
Jesper Enander
DDDiana Radu Djurfeldt
Diana Radu Djurfeldt
BLBrjánn Ljótsson
Brjánn Ljótsson
CRChristian Rück
Christian Rück
Although cognitive behavioral therapy (CBT) is an effective treatment for obsessive-compulsive disorder (OCD), with responder rates averaging 62% to 72%1,2 a significant proportion of patients do not achieve satisfactory symptom relief. One possible way to further improve treatment efficacy is to enhance CBT with pharmacotherapy. Serotonin reuptake inhibitors are effective for OCD in their own right, but no synergistic effects of the 2 treatment modalities have been convincingly demonstrated compared with CBT alone.3 One compound that has shown promise as an adjunct to CBT for OCD is d-cycloserine (DCS).4 It affects the glutamate system by acting as a partial agonist at the N-methyl-d-aspartate (NMDA) receptor, which is crucially implicated in fear learning and fear extinction in both rats and humans.4 Specifically, NMDA antagonists block fear extinction in rats, whereas NMDA agonists enhance fear extinction.5 In CBT for OCD, patients gradually face anxiety-provoking cues and simultaneously refrain from carrying out rituals, an approach known as exposure with response prevention (ERP).6 As ERP is based on the principles of fear extinction, DCS may be a viable augmentation strategy for these patients. To date, 3 of 5 randomized clinical trials of DCS-augmented CBT for OCD have found that DCS augmentation may lead to a faster treatment response than placebo, but results are inconsistent as to whether DCS is superior to placebo at posttreatment or follow-up.7-11 However, these previous trials had modest sample sizes (N = 24-30) and may therefore have been underpowered to detect subtle differences between DCS and placebo. Additional variables such as number of CBT sessions, the dose and number of DCS capsules, the timing of drug administration, and the success of the exposure sessions may also contribute to the conflicting results obtained to date.12-14